Mepolizumab for treatment of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - A pilot study

Not Applicable

Recruiting

• Conditions: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome; Inflammatory and Immune System - Allergies

• Registration Number: ACTRN12621001333808
• Lead Sponsor: St Vincent's Hospital, Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-10-05
• Last Update Posted: 3 October 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

Adult patients (18 years old and above) who are diagnosed with DRESS syndrome (based on the RegiSCAR criteria) and with eosinophil count >0.8 x 10^9/L.

Exclusion Criteria

those with other eosinophilic disorders or concurrent parasitic infection, pregnant or breastfeeding patients, children and those who are unable to give informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified